Certis Oncology Team

5
Nov

NOV 5, 2018: Certis Oncology’s Dr. Fritz Eilber: This Evidence is the Best that Currently Exists

Fritz Eilber, MD, UCLA Surgery Division of Oncology discusses why he joined the Board of Directors at Certis Oncology. Certis provides Orthotopic PDX (Patient-Derived Xenograft) mouse models for cancer patients.  

25
Oct

OCT 25, 2018: CERTIS ONCOLOGY COLLABORATES WITH SCIENCE EXCHANGE TO OFFER ON-DEMAND ACCESS TO ITS ORTHOTOPIC PDX SERVICES

CERTIS ONCOLOGY COLLABORATES WITH SCIENCE EXCHANGE TO OFFER ON-DEMAND ACCESS TO ITS ORTHOTOPIC PDX SERVICES SAN DIEGO, OCTOBER 25, 2018. Science Exchange, the leading marketplace for outsourced R&D, and Certis Oncology, a leading provider for preclinical mouse modeling and tumor banking services, announced they are working together to bring Certis’ breakthrough orthotopic PDX-based CRO services to the global research community

Read more

19
Aug

AUG 18, 2018: Orthotopic PDX Models with Quantitative Pathology End Points Provide a New Standard in Translational Oncology Drug Development

By: Marisa Keller Orthotopic Patient-Derived Xenografts (PDX) Despite the rise of personalized approaches to the treatment of cancer, translating these therapies into a clinical setting still poses an exceptional challenge. This is highlighted in drug development where research into targeted therapies requires highly characterized tools that mimic human tumors as closely as possible. Patient-derived Xenografts (PDXs) are one such tool

Read more